Search the Newsreel

Can Precigen (PGEN) Justify Its Valuation On Earnings And PAPZIMEOS Launch?

Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation

This article examines PepGen's cash burn rate and its implications for the company's future. It highlights the importance of monitoring cash burn for early-stage biotechnology companies like PepGen, especially given its significant clinical trial expenses. The analysis suggests that while the company has a …

HC Wainwright Has Positive Outlook of PepGen FY2027 Earnings

HC Wainwright has updated its financial outlook for PepGen, raising the FY2027 EPS estimate to a loss of $1.78 per share and maintaining a "Buy" rating. The firm also projects a $1.33-per-share loss for FY2029. PepGen currently holds a "Moderate Buy" consensus rating from …

PepGen Inc (PEPG) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for PepGen Inc (PEPG), detailing analyst ratings, price targets, and EPS estimates. Based on 8 analysts, the stock has a "Buy" trend with a target price of $9.00, representing a significant upside. The article also includes recent and …

Precigen (PGEN) Could Be 50% Undervalued On Strong Earnings Turnaround

PepGen Inc. (PEPG) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of August 8, 2025 Deadline

Levi & Korsinsky LLP has announced a class action lawsuit against PepGen Inc. (PEPG), reminding investors of the August 8, 2025 deadline to join. The lawsuit alleges that PepGen made false and misleading statements regarding the efficacy and safety of its lead product candidate, …

PepGen (NASDAQ:PEPG) Posts Earnings Results, Beats Estimates By $0.02 EPS

Is PepGen (NASDAQ:PEPG) In A Good Position To Invest In Growth?

PepGen (NASDAQ:PEPG) has seen its share price increase by 166% over the last year, despite not yet generating revenue. The company had a cash runway of approximately 20 months as of June 2026, with a cash burn of US$69m and US$117m in cash. While …

Precigen (PGEN) Insider Rutul Shah Sells 32,739 Shares

Precigen (PGEN) insider Rutul Shah sold 32,739 shares of the company on August 6, 2026, totaling approximately $224,589. This transaction is part of a larger pattern where insiders have sold significantly more shares than they purchased over the past year. Despite the stock trading …

PepGen Inc. Stock 12‑Month Price Target Cut to $10.19, Implies 323% Upside

Analysts have revised PepGen Inc.'s average 12-month price target down slightly from $10.25 to $10.19, implying a significant 323% potential upside from its Aug. 6 closing price. The consensus rating remains a "Buy" from 8 covering analysts, with the highest target at $20 and …

COO sale: Precigen (PGEN) insider trades 32,739 shares via plan

Precigen's Chief Operating Officer, Rutul R Shah, sold 32,739 shares of common stock at $6.86 per share on August 6, 2026, through a Rule 10b5-1 trading plan. Following this transaction, Shah directly holds 465,012 shares. The sale amounted to approximately $225,000, and the filing …

PepGen - Cash of $117.20 Mln as of June 30, 2

This article provides a brief update on PepGen's financial position, stating that the company had cash reserves of $117.20 million as of June 30, 202X. The content is very minimal, focusing solely on this specific financial figure.

Results: Precigen, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

The article discusses how Precigen, Inc. exceeded expectations, leading analysts to update their financial estimates for the company. This suggests a positive outlook for Precigen's future performance based on recent results.

Precigen (PGEN) Is Up 16.3% After Papsimios-Fueled Return To Profitability And Broad Payer Coverage

Precigen (PGEN) reported a significant return to profitability in Q2 2026, driven by strong revenue and net income largely attributed to the rapid uptake of Papsimios. The company's profitability and broad payer coverage, along with seven-year FDA market exclusivity for Papsimios, strengthen its investment …

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

PepGen Inc. announced that its independent Data and Safety Monitoring Board (DSMB) has recommended advancing the Phase 2 FREEDOM2-DM1 study of PGN-EDODM1 into its highest multiple ascending dose cohort of 12.5 mg/kg, without changes to the study protocol. The DSMB also advised dose escalation …

Precigen (NASDAQ: PGEN) Form 144 covers 32,739 common shares for sale

Precigen, Inc. has filed a Form 144 notice for the sale of 32,739 common shares with an aggregate value of $224,589.54 through Fidelity Brokerage Services LLC on NASDAQ. These shares were originally acquired through restricted stock vesting as compensation on three different dates between …

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

PepGen Inc. reported its second quarter 2026 financial results and recent corporate highlights, announcing that its PGN-EDODM1 program for Myotonic Dystrophy Type 1 is advancing. The DSMB recommended escalating PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study and increasing the dose in …

PepGen Q2 2026 earnings: Lower R&D spending narrows the net loss

PepGen (Nasdaq: PEPG) reported a narrowed net loss of $17.8 million for Q2 2026, down from $23.1 million in Q2 2025, primarily due to a significant reduction in R&D expenses. The company ended the quarter with $117.2 million in cash and expects these funds …

PepGen Inc. 1H 2026: Net loss $(35.6M), EPS $(0.51) — 10-Q Summary

PepGen Inc. reported a consolidated net loss of $(35.6M) and diluted EPS of $(0.51) for the first half of 2026, an improvement compared to the previous year. The company holds $117.2M in cash and marketable securities, which management states will support operations into Q4 …

PepGen advances DM1 trial to highest dose cohort By Investing.com

PepGen Inc. announced that its Phase 2 FREEDOM2-DM1 study of PGN-EDODM1 for myotonic dystrophy type 1 will advance to the highest dose cohort of 12.5 mg/kg, following a positive safety review. The independent Data and Safety Monitoring Board found no serious adverse events or …

Precigen (PGEN) Stock Rallies As PAPZIMEOS Delivers First Clean Profit

Precigen (PGEN) stock rallied 5.5% after the company reported its first profitable quarter, driven by strong sales of its new therapy, PAPZIMEOS, for recurrent respiratory papillomatosis. Q2 revenue reached US$55 million, with PAPZIMEOS contributing US$53.1 million, resulting in a net income of US$20.1 million. …

Germantown biopharma Precigen turns first quarterly profit after key drug scores FDA approval

Germantown-based biopharma company Precigen Inc. has reported its first quarterly profit. This achievement comes a year after its immunotherapy drug received FDA approval, with sales of the drug being the main driver of the profit.

PRECIGEN, INC. 2026: Revenue $54.98M, EPS $0.05— 10-Q Summary

PRECIGEN, INC. (PGEN) reported strong results for the quarter ending 2026, with revenue reaching $54.98 million and diluted EPS at $0.05, significantly improving from the prior year. This growth was primarily driven by the successful commercial launch of Papzimeos, following its FDA approval in …

Class Action Filed Against PepGen Inc. (PEPG) Over Securities Violations - Contact Levi & Korsinsky Today

A class action lawsuit has been filed against PepGen Inc. (NASDAQ: PEPG) alleging securities fraud between March 7, 2024, and March 3, 2025. The lawsuit claims that PepGen made false statements about the effectiveness and safety of its lead product candidate, PGN-EDO51, and that …

Precigen Price Target Maintained With a $14.00/Share by HC Wainwright & Co.

HC Wainwright & Co. has reiterated its Buy rating for Precigen, maintaining a price target of $14.00 per share. This indicates continued analyst confidence in the company's stock performance.

Precigen (NASDAQ:PGEN) Announces Earnings Results

Levi & Korsinsky Urges PepGen Inc. (PEPG) Shareholders to Act Before Lead Plaintiff Deadline August 8, 2025

Levi & Korsinsky is urging shareholders of PepGen Inc. (NASDAQ: PEPG) who suffered losses on their investment between March 7, 2024, and March 3, 2025, to act before the lead plaintiff deadline of August 8, 2025. A class action securities lawsuit alleges that PepGen …

Precigen (PGEN) Stock Rises on Q2 2026 Earnings

Precigen, Inc. reports results for the quarter ended June 30 - Earnings Summary

Precigen, Inc. has released its earnings summary for the quarter that concluded on June 30. The article is from Refinitiv and is hosted on TradingView, which also offers access to news from Reuters and other sources.

Precigen GAAP EPS of $0.05 beats by $0.06, revenue of $54.98M beats by $27.15M

* Precigen press release [https://seekingalpha.com/pr/20606749-precigen-reports-second-quarter-2026-financial-results-highlighted-by-accelerating-papzimeos] (PGEN [https://seekingalpha.com/symbol/PGEN]): Q2 GAAP EPS of $0.05 beats by $0.06. * Revenue of $54.98M beats by $27.15M. MORE ON PRECIGEN * Precigen: Entering The Oncology 'Sweet Spot' [https://seekingalpha.com/article/4918147-precigen-entering-the-oncology-sweet-spot] * Precigen, Inc. (PGEN) Presents at Goldman Sachs 47th Annual Global …

Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth

Precigen announced strong second-quarter 2026 financial results, driven by accelerated revenue growth from its PAPZIMEOS treatment, which generated $53.1 million. The company achieved quarterly profitability and expects to reach cash flow break-even by the end of 2026, supported by broad U.S. adoption, seven-year market …

Precigen, Inc. (PGEN) Q2 Earnings and Revenues Surpass Estimates

Precigen, Inc. (PGEN) reported Q2 earnings of $0.05 per share, significantly surpassing the Zacks Consensus Estimate of a $0.02 loss, and revenues of $54.98 million, exceeding expectations by 97.62%. The company has outperformed the S&P 500 this year with a 58.1% gain, and currently …

Precigen earnings set to test gene therapy growth trajectory

Precigen Inc. is set to announce its second-quarter results, with investors keenly watching for continued revenue growth from its PAPZIMEOS gene therapy launch and progress towards profitability. Analysts anticipate a loss of $0.01 per share on $27.83 million in revenue, driven by strong market …